Teacher Retirement System of Texas Has $752,000 Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)

Teacher Retirement System of Texas grew its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) by 58.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,390 shares of the company’s stock after purchasing an additional 6,388 shares during the quarter. Teacher Retirement System of Texas’ holdings in Scholar Rock were worth $752,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Intech Investment Management LLC bought a new position in Scholar Rock during the third quarter worth $202,000. Charles Schwab Investment Management Inc. grew its position in Scholar Rock by 9.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company’s stock worth $4,027,000 after purchasing an additional 42,139 shares during the last quarter. FMR LLC raised its position in shares of Scholar Rock by 3.1% during the third quarter. FMR LLC now owns 10,196,046 shares of the company’s stock valued at $81,670,000 after buying an additional 308,813 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Scholar Rock by 900.6% in the third quarter. BNP Paribas Financial Markets now owns 36,331 shares of the company’s stock valued at $291,000 after buying an additional 32,700 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Scholar Rock by 7.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company’s stock worth $759,000 after buying an additional 6,269 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Stock Performance

NASDAQ SRRK opened at $32.84 on Monday. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a market cap of $3.11 billion, a P/E ratio of -13.97 and a beta of 0.59. The company’s 50-day simple moving average is $37.74 and its 200 day simple moving average is $33.23.

Analyst Ratings Changes

Separately, Wedbush reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $42.67.

Insider Buying and Selling at Scholar Rock

In other news, insider Jing L. Marantz sold 5,655 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the completion of the sale, the insider now owns 67,200 shares of the company’s stock, valued at approximately $2,970,240. This trade represents a 7.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Edward H. Myles sold 142,292 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the completion of the transaction, the chief financial officer now directly owns 111,345 shares in the company, valued at $3,966,108.90. The trade was a 56.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 299,772 shares of company stock valued at $11,245,798. 19.20% of the stock is currently owned by corporate insiders.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.